Published in MAbs on January 01, 2015
Enhancement of Immune Effector Functions by Modulating IgG's Intrinsic Affinity for Target Antigen. PLoS One (2016) 0.84
A comparison of anti-HER2 IgA and IgG1 in vivo efficacy is facilitated by high N-glycan sialylation of the IgA. MAbs (2015) 0.78
Successive site translocating inoculation potentiates DNA/recombinant vaccinia vaccination. Sci Rep (2015) 0.75
Enhancement of antibody functions through Fc multiplications. MAbs (2017) 0.75
Functionally Active Fc Mutant Antibodies Recognizing Cancer Antigens Generated Rapidly at High Yields. Front Immunol (2017) 0.75
Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol (2010) 6.04
The intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood (2001) 2.92
Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat Biotechnol (1999) 2.44
A formalin-fixed, paraffin-processed cell line standard for quality control of immunohistochemical assay of HER-2/neu expression in breast cancer. Am J Clin Pathol (2002) 2.13
The glycosylation and structure of human serum IgA1, Fab, and Fc regions and the role of N-glycosylation on Fcα receptor interactions. J Biol Chem (1998) 2.10
OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy. Immunol Cell Biol (2014) 2.02
Neutrophils mediate antibody-induced antitumor effects in mice. Blood (2013) 1.66
Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells. Mol Cancer Ther (2008) 1.61
Cellular distribution, regulation, and biochemical nature of an Fc alpha receptor in humans. J Exp Med (1990) 1.60
Insights into IgA-mediated immune responses from the crystal structures of human FcalphaRI and its complex with IgA1-Fc. Nature (2003) 1.53
Optimization of Fc-mediated effector functions of monoclonal antibodies. Curr Opin Biotechnol (2009) 1.30
Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies. Expert Opin Biol Ther (2006) 1.28
Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions. MAbs (2011) 1.27
Metabolic properties of human IgA subclasses. Clin Exp Immunol (1973) 1.26
FcalphaRI-positive liver Kupffer cells: reappraisal of the function of immunoglobulin A in immunity. Nat Med (2000) 1.19
Immunoglobulin A-mediated protection against Bordetella pertussis infection. Infect Immun (2001) 1.19
Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies. Cancer Metastasis Rev (2005) 1.16
The IgA system: a comparison of structure and function in different species. Vet Res (2006) 1.16
IgG effector mechanisms. Chem Immunol (1997) 1.15
Polymorphonuclear neutrophils and cancer: intense and sustained neutrophilia as a treatment against solid tumors. Med Res Rev (2011) 1.07
A novel human IgA monoclonal antibody protects against tuberculosis. J Immunol (2011) 1.07
Effective phagocytosis of low Her2 tumor cell lines with engineered, aglycosylated IgG displaying high FcγRIIa affinity and selectivity. ACS Chem Biol (2012) 0.97
Effector mechanisms of recombinant IgA antibodies against epidermal growth factor receptor. J Immunol (2007) 0.96
Antibody-dependent cell-mediated cytotoxicity effector-enhanced EphA2 agonist monoclonal antibody demonstrates potent activity against human tumors. Neoplasia (2009) 0.95
The human Fc receptor for IgA (Fc alpha RI, CD89) on transgenic peritoneal macrophages triggers phagocytosis and tumor cell lysis. Immunol Lett (1999) 0.95
FcalphaRI (CD89) as a novel trigger molecule for bispecific antibody therapy. Blood (1997) 0.93
Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing. Blood (2002) 0.92
IgA antibodies for cancer therapy. Crit Rev Oncol Hematol (2001) 0.92
The surface membrane antigen phenotype of human blood basophils. Allergy (1994) 0.88
Th1 cytokines are more effective than Th2 cytokines at licensing anti-tumour functions in CD40-activated human macrophages in vitro. Eur J Immunol (2013) 0.88
IgA EGFR antibodies mediate tumour killing in vivo. EMBO Mol Med (2013) 0.88
IgA enhances NETosis and release of neutrophil extracellular traps by polymorphonuclear cells via Fcα receptor I. J Immunol (2014) 0.85
Characterization of a mutated IgA2 antibody of the m(1) allotype against the epidermal growth factor receptor for the recruitment of monocytes and macrophages. J Biol Chem (2012) 0.85
Targeting regulatory T cells in tumor immunotherapy. Immunol Cell Biol (2014) 0.83
Hybrid IgA2/IgG1 antibodies with tailor-made effector functions. Clin Immunol (2001) 0.82
Effect of a tail piece cysteine deletion on biochemical and functional properties of an epidermal growth factor receptor-directed IgA2m(1) antibody. MAbs (2014) 0.82
Enhancement of polymorphonuclear cell-mediated tumor cell killing on simultaneous engagement of fcgammaRI (CD64) and fcalphaRI (CD89). Cancer Res (2001) 0.82
Immunophenotypic and functional characterization of human tonsillar mast cells. J Leukoc Biol (1997) 0.80
Immunoglobulin A: Fc(alpha)RI interactions induce neutrophil migration through release of leukotriene B4. Gastroenterology (2009) 0.80
IgGA: a "cross-isotype" engineered human Fc antibody domain that displays both IgG-like and IgA-like effector functions. Chem Biol (2014) 0.80
Neutrophils in antibody-based immunotherapy of cancer. Expert Opin Biol Ther (2008) 0.79
Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol (2007) 8.33
Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem (2006) 2.58
Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. J Immunol (2002) 2.00
DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo. Cancer Res (2011) 1.78
Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutation. Nat Clin Pract Oncol (2006) 1.55
The role of the CD44 transmembrane and cytoplasmic domains in co-ordinating adhesive and signalling events. J Cell Sci (2004) 1.55
MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol (2010) 1.41
Regulating the regulator: negative regulation of Cbl ubiquitin ligases. Trends Biochem Sci (2006) 1.40
Deubiquitinases regulate the activity of caspase-1 and interleukin-1β secretion via assembly of the inflammasome. J Biol Chem (2012) 1.40
A general method for greatly improving the affinity of antibodies by using combinatorial libraries. Proc Natl Acad Sci U S A (2005) 1.37
Hyper-responsiveness of IPF/UIP fibroblasts: interplay between TGFbeta1, IL-13 and CCL2. Int J Biochem Cell Biol (2008) 1.36
Structural characterization of a mutated, ADCC-enhanced human Fc fragment. Mol Immunol (2008) 1.34
Modulation of the effector functions of a human IgG1 through engineering of its hinge region. J Immunol (2006) 1.25
A human antibody-drug conjugate targeting EphA2 inhibits tumor growth in vivo. Cancer Res (2008) 1.25
Structural characterization of a human Fc fragment engineered for lack of effector functions. Acta Crystallogr D Biol Crystallogr (2008) 1.24
Structural characterization of a human Fc fragment engineered for extended serum half-life. Mol Immunol (2009) 1.19
Characterization of the epitope for anti-human respiratory syncytial virus F protein monoclonal antibody 101F using synthetic peptides and genetic approaches. J Gen Virol (2007) 1.15
The design and characterization of oligospecific antibodies for simultaneous targeting of multiple disease mediators. J Mol Biol (2009) 1.14
Structural insights into neonatal Fc receptor-based recycling mechanisms. J Biol Chem (2014) 1.10
B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody. J Pharmacol Exp Ther (2010) 1.09
The collagen receptor Endo180 (CD280) Is expressed on basal-like breast tumor cells and promotes tumor growth in vivo. Cancer Res (2007) 1.07
Molecular basis for antagonistic activity of anifrolumab, an anti-interferon-α receptor 1 antibody. MAbs (2015) 1.04
Respiratory syncytial virus-neutralizing monoclonal antibodies motavizumab and palivizumab inhibit fusion. J Virol (2010) 1.03
Improving target cell specificity using a novel monovalent bispecific IgG design. MAbs (2015) 1.02
De novo selection of high-affinity antibodies from synthetic fab libraries displayed on phage as pIX fusion proteins. J Mol Biol (2010) 0.97
A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo. Br J Haematol (2011) 0.97
Antibody-dependent cell-mediated cytotoxicity effector-enhanced EphA2 agonist monoclonal antibody demonstrates potent activity against human tumors. Neoplasia (2009) 0.95
The CEA/CD3-bispecific antibody MEDI-565 (MT111) binds a nonlinear epitope in the full-length but not a short splice variant of CEA. PLoS One (2012) 0.91
Multivalent scaffold proteins as superagonists of TRAIL receptor 2-induced apoptosis. Mol Cancer Ther (2013) 0.89
Antibody humanization by framework shuffling. Methods (2005) 0.87
Crystallization and preliminary X-ray diffraction analysis of the complex between a human anti-alpha toxin antibody fragment and alpha toxin. Acta Crystallogr Sect F Struct Biol Cryst Commun (2013) 0.86
CD19 and CD32b differentially regulate human B cell responsiveness. J Immunol (2014) 0.85
Structural and functional characterization of an agonistic anti-human EphA2 monoclonal antibody. J Mol Biol (2011) 0.84
Insights into the molecular basis of a bispecific antibody's target selectivity. MAbs (2015) 0.84
Tailor-made antibody therapeutics. Methods (2005) 0.84
Antibody Fab display and selection through fusion to the pIX coat protein of filamentous phage. J Immunol Methods (2010) 0.83
Recombinant respiratory syncytial virus F protein expression is hindered by inefficient nuclear export and mRNA processing. Virus Genes (2010) 0.83
Crystallization and preliminary X-ray diffraction analysis of the complex between a human anti-interferon antibody fragment and human interferon alpha-2A. Acta Crystallogr Sect F Struct Biol Cryst Commun (2008) 0.82
Framework shuffling of antibodies to reduce immunogenicity and manipulate functional and biophysical properties. Mol Immunol (2007) 0.81
Humanized antibodies and their applications. Methods (2005) 0.78
Targeting the junction of CɛmX and ɛ-migis for the specific depletion of mIgE-expressing B cells. Mol Immunol (2012) 0.77
A mammalian expression system for high throughput antibody screening. J Immunol Methods (2013) 0.77
Analysis of human and primate CD2 molecules by protein sequence and epitope mapping with anti-human CD2 antibodies. Mol Immunol (2004) 0.76
Crystallization and preliminary X-ray diffraction analysis of the complex of a human anti-ephrin type-A receptor 2 antibody fragment and its cognate antigen. Acta Crystallogr Sect F Struct Biol Cryst Commun (2010) 0.76
Prevention of Respiratory Syncytial Virus Infection: From Vaccine to Antibody. Microbiol Spectr (2014) 0.75
Synthetic, site-specific biotinylated analogs of human MCP-1. J Pept Sci (2006) 0.75
Synthesis and biological characterization of human monocyte chemoattractant protein 1 (MCP-1) and its analogs. J Pept Sci (2006) 0.75
A Nanoparticle Platform To Evaluate Bioconjugation and Receptor-Mediated Cell Uptake Using Cross-Linked Polyion Complex Micelles Bearing Antibody Fragments. Biomacromolecules (2016) 0.75